News

News Subscription

Nov 05. 2015
Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553
Read more
Download
Oct 23. 2015
Basilea announces that European Commission maintained isavuconazole's orphan drug status
Read more
Download
Oct 17. 2015
Basilea announces filing of registration statement for a proposed offering in the United States
Read more
Download
Oct 16. 2015
Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union
Read more
Download
Oct 15. 2015
Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC
Read more
Download
Oct 12. 2015
Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections
Read more
Download
Sep 07. 2015
Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program
Read more
Download
Aug 28. 2015
Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Günter Ditzinger named as successor
Read more
Download
Aug 14. 2015
Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA® and Zevtera®
Read more
Download
Aug 12. 2015
Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections
Read more
Download